卡瑞利珠单抗联合SP化疗方案治疗局部晚期食管癌临床疗效及对细胞免疫、预后的影响

doi:10.3969/j.issn.1001-8131.2026.02.004

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1286 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore clinical curative effect of camrelizumab combined with S-1 plus cisplatin(SP)chemotherapy in advanced esophageal cancer and its influences on cellular immune function and prognosis. Methods A total of 202 patients with advanced esophageal cancer treated in The Second People's Hospital of Jiaozuo were enrolled between March 2021 and June 2024.According to random number table method,they were divided into control group(101 cases,SP chemotherapy regimen)and observation group(101 cases,camrelizumab combined with SP chemotherapy regimen).The clinical curative effect,serum tumor markers(CEA,CA19-9,CYFRA21-1,SCC),T lymphocyte subsets(CD3⁺,CD4⁺,CD8⁺)and the occurrence of adverse reactions were compared between the two groups. Results After treatment,objective response rate(ORR)and disease control rate(DCR)in observation group were and（P<0.05）,higher than those in control group.The levels of CEA,CA19-9,CYFRA21-1 and SCC in observation group were（P<0.05）,lower than those in control group The levels of peripheral blood CD3⁺,CD4⁺ and CD4⁺/CD8⁺ in observation group were higher than those in control group（P<0.05）,while CD8⁺ was lower than that in control group.The differences in all the above indexes between the two groups were statistically significant(P<0.05).In terms of safety,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After 1 year of follow-up,cumulative survival rate in observation group was higher than that in control group(Log-rank χ²=9.221,P=0.002). Conclusion The combination therapy of camrelizumab and SP regimen can significantly improve curative effect and survival status in patients with advanced esophageal cancer by significantly down-regulating tumor indexes and activating immune function.

Key words： Advanced esophageal cancer SP chemotherapy Camrelizumab Cellular immunity Prognosis

Received: 15 February 2026

PACS:

R735.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Fu Peibiao
	Chen Yanmin
	Wang Zhenzhen
	Zhang Yanyan
	Zheng Huihui

Cite this article:

Fu Peibiao,Chen Yanmin,Wang Zhenzhen, et al. Clinical Curative Effect of Camrelizumab Combined with SP Chemotherapy in Advanced Esophageal Cancer and Its Influences on Cellular Immunity and Prognosis[J]. journal1, 2026, 46(2): 14-18.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2026.02.004 OR http://www.hrbyybjb.org.cn/EN/Y2026/V46/I2/14

[1] JIANG W,ZHANG B,XU J,et al.Current status and perspectives of esophageal cancer:a comprehensive review.Cancer Commun(Lond),2025,45(3):281-331.
[2] 栗晓咪,李莉,丁晓燕,等.抗血管生成药物联合免疫检查点阻滞剂在晚期肝细胞癌中的研究[J].胃肠病学和肝病学杂志,2021,30(11):1212-1218.
[3] 季洪兵,潘建基,刘文晖.外放疗联合仑伐替尼和卡瑞利珠单抗治疗不可切除肝癌的疗效与安全性评价[J].中国肿瘤,2024,33(5):420-427.
[4] 闫雷,芦亚楠,李红,等.卡瑞利珠单抗联合TACE治疗晚期原发性肝癌的疗效及其对血清T淋巴细胞、AFP-L3等的影响[J].临床和实验医学杂志,2024,23(14):1490-1493.
[5] 王雪,赵鸿鹰,李文广,等.替吉奥联合顺铂治疗HER-2阴性胃癌患者的临床疗效和安全性评估[J].中国药物应用与监测,2023,20(4):226-230.
[6] 汤少鹏,周晓蕾,陈家令.卡瑞利珠单抗联合化疗在Ⅲ期NSCLC患者术前新辅助治疗中的应用效果[J].实用癌症杂志,2025,40(2):214-217.
[7] 陈涛,冯光强,高兴才.替雷利珠单抗联合SP方案化疗治疗晚期食管癌患者的临床疗效[J].癌症进展,2024,22(21):2359-2361,2365.
[8] 中国临床肿瘤学会指南工作委员会.食管癌诊疗指南(2020版)[M].北京:人民卫生出版社,2020.
[9] Eisenhauer EA,Therasse P,Bogaerts J,et al.New respon-seevaluation criteria in solid tumours;revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228.
[10] 宋芬芬,李胜棉.基于卡瑞利珠单抗的方案治疗局部晚期及转移性食管癌的真实世界研究[J].中国全科医学,2025,28(7):844-852.
[11] 马丹丹,吴圆圆,陈婧,等.卡瑞利珠单抗联合nab-PC方案对晚期驱动基因阴性NSCLC的疗效及免疫功能的影响[J].广东医学,2024,45(3):376-381.
[12] 韩双,郭晓波,翟华丽,等.5种肿瘤标志物在食管鳞癌患者血清中的表达及对预后的影响分析[J].检验医学与临床,2023,20(6):792-796.
[13] 轩菡,李皓吾,林国和,等.卡瑞利珠单抗联合化疗治疗晚期食管癌患者的临床研究[J].中国临床药理学杂志,2024,40(16):2316-2319.
[14] 张铭博,宋羽霄,章必成.肿瘤相关巨噬细胞和T细胞亚群相互作用的研究进展[J].重庆医科大学学报,2025,50(6):714-720.
[15] BATTRAM AM,BACHILLER M,MARTíN-ANTONIO B.Senescence in the Development and Response to Cancer with Immunotherapy:A Double-Edged Sword[J].Int J Mol Sci,2020,21(12):4346.
[16] 吕青芳,张鹏,李桂香.PD-1单抗联合化疗对非小细胞肺癌患者淋巴细胞亚群的影响及疗效和预后的相关分析[J].中国肿瘤生物治疗杂志,2025,32(1):73-78.
[17] FUMET JD,LIMAGNE E,THIBAUDIN M,et al Immuno-genic Cell Death and Elimination of Immunosuppressive Cells:A Double-Edged Sword of Chemotherapy[J].Cancers(Basel),2020,12(9):2637.
[18] 曹亚男,赵成秀,张雪,等.卡瑞利珠单抗联合AP方案治疗晚期非鳞癌非小细胞肺癌的临床研究[J].国际呼吸杂志,2022,42(23):1788-1795.
[19] 杨晶,张庆桥,魏宁,等.DEB-TACE联合卡瑞利珠单抗治疗中晚期肝癌的临床疗效及对肿瘤标志物和T淋巴细胞亚群的影响[J].现代生物医学进展,2023,23(18):3596-3600.
[20] 王冬苗,范仲英,税明才.卡瑞利珠单抗联合化疗治疗食管鳞状细胞癌的疗效及对血清癌胚抗原、SCC、VEGF水平和免疫功能的影响[J].临床和实验医学杂志,2024,23(13):1396-1400.
[21] 杜尚云,翁莉,武敏.TACE联合卡瑞利珠单抗治疗中晚期原发性肝癌患者临床疗效研究[J].实用肝脏病杂志,2023,26(1):116-119.
[22] 张志明,徐明静,刘茜红,等.卡瑞利珠单抗联合白蛋白紫杉醇和卡铂治疗晚期食管癌的临床研究[J].现代药物与临床,2024,39(6):1564-1570.
[23] LIU Y,WANG Z,WU B,et al.PD-1 inhibitors combined with chemotherapy versus chemotherapy alone:efficacy and prognostic analysis in recurrent metastatic nasopharyngeal carcinoma[J].Am J Transl Res,2024,16(6):2622-2632.